Dermatology News and Research

Latest Dermatology News and Research

KYTHERA Biopharmaceuticals presents its two Phase 2 clinical study results

KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today presented detailed results from two double-blind Phase 2 studies, each designed to evaluate the safety and effectiveness of ATX-101, a first-in-class injectable drug for the reduction of small volumes of fat.

3 Oct 2009

First prescription foam formulation of benzoyl peroxide available

Onset Therapeutics, a specialty pharmaceutical company focused on dermatology, announced today the commercial availability of BenzEFoam (benzoyl peroxide) 5.3% Emollient Foam, the first prescription foam formulation of benzoyl peroxide.

1 Oct 2009

Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption

Halozyme Therapeutics, Inc. today announced additional Phase 2 results that demonstrated faster insulin absorption and increased peak insulin concentrations in type 1 diabetic patients after co-administration of its recombinant hyaluronidase enzyme (rHuPH20 or PH20) with Humulin® R (regular human insulin), a mealtime insulin.

1 Oct 2009

TriPollar technology effective in reducing stretch marks

Dr. Worophong Manuskiatti has been invited to present results of his study "Treatment of striae distensae in skin phototypes IV-V with a TriPollar radiofrequency device" in the upcoming meeting of the European Academy of Dermatology and Venereology (EADV) Conference held on October 7-10, 2009 in Berlin, Germany.

1 Oct 2009

Two-thirds of women say psoriasis negatively affects their overall emotional well-being

Women with psoriasis and psoriatic arthritis are markedly more likely than men to suffer from the emotional and psychological effects of the diseases, according to survey data released by the National Psoriasis Foundation today.

1 Oct 2009

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 1 study of PV-10 for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. PV-10 is the company’s lead oncology drug candidate that is also currently undergoing Phase 2 study for metastatic melanoma.

1 Oct 2009

Intoxicated trauma patients have higher survial rates than sober patients: Study

Trauma patients who were intoxicated before their injuries were more likely to survive than trauma patients who suffered similar injuries but were sober at the time, according to a study published in the October edition of the American Surgeon that was conducted by researchers at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed).

1 Oct 2009

Lumenis announces launch of the AcuPulse Fractional CO2 Laser System for Aesthetics

Lumenis Inc., a global developer, manufacturer and seller of laser, light-based and radio-frequency devices for surgical, aesthetic, and ophthalmic applications, announced today the launch of the AcuPulse(TM) Fractional CO2 Laser System for aesthetic applications at the American Society of Dermatologic Surgery's annual meeting in Phoenix this week.

From Lumenis Inc. 1 Oct 2009

Valeant Pharmaceuticals to acquire Private Formula International Holdings

Valeant Pharmaceuticals International (NYSE: VRX) today announced that it has agreed to acquire Private Formula International Holdings Pty Limited, a leading skincare company.

1 Oct 2009

Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis

Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to severe Psoriasis; the study successfully met its primary objective of efficacy and safety

1 Oct 2009

NHGRI announces grant to establish Wisconsin Center of Excellence in Genomics Science

The National Human Genome Research Institute (NHGRI) of the National Institutes of Health today announced an $8 million, three-year grant to establish a Wisconsin Center of Excellence in Genomics Science.

29 Sep 2009

Halozyme Therapeutics announces Phase 1 clinical study to assess three insulin analogs

Halozyme Therapeutics, Inc. today announced the commencement of a Phase 1 clinical study that will assess the effects of three approved prandial (mealtime) insulin analogs administered with its proprietary rHuPH20 (PH20) hyaluronidase enzyme compared to each of the analogs alone. This randomized, three-way cross-over design, euglycemic clamp study will compare the postprandial pharmacokinetics (PK) and glucodynamics (GD) of the insulin analogs.

28 Sep 2009

Child health experts to gather in Italy for Excellence in Paediatrics conference

Obesity, the flu pandemic and diabetes are just three of the hot topics that will be explored when top child health experts gather in Italy for Excellence in Paediatrics from 3 to 6 December 2009.

28 Sep 2009

Rio Grande Dermatology offers eyelash drugs for $99

Many women desire to have thicker and longer eyelashes. Previously this could only be accomplished with the use of fake lashes. However, due to the discovery of a desirable side effect of a glaucoma drug, Latisse was born. Rio Grande Dermatology, providers of comprehensive dermatology treatments for the Albuquerque metropolitan area, is proud to offer this highly anticipated "eyelash drug" for an introductory price of $99 dollars.

24 Sep 2009

Symposium on genetics of psoriasis and psoriatic arthritis to be held

A symposium about “Pharmacogenomics In Dermatology And Cosmetics” will be presented on Thursday, October 8 to coincide with the 18th European Academy of Dermatology and Venereology (EADV) Congress. It will be held at the Kempinski Hotel Bristol - Salon Charlottenburg-Cecilienhof, Kurfürstendamm 27, D-10719, Berlin, Germany.

24 Sep 2009

NIHR to fund patient panel for skin disease research

People who suffer from skin disease are being asked to help make research more effective by joining a new 'Patient Panel'.

24 Sep 2009

LEO Pharma re-acquires product licensing rights from Warner Chilcott

Warner Chilcott plc (Nasdaq: WCRX) and LEO Pharma announced today that, in exchange for a one-time cash payment of $1.0 billion to Warner Chilcott, LEO Pharma is re-acquiring Warner Chilcott's exclusive product licensing rights in the United States to its topical psoriasis treatments Taclonex(R), Taclonex Scalp(R), Dovonex(R) as well as rights to all products in LEO's development pipeline, and acquiring all inventories of the products.

24 Sep 2009

Advanced Hair Studio to introduce genetic baldness tests in Australia

Men and women in Australia now have access to genetic tests for predicting the risk of male or female hair loss thanks to a distribution agreement announced today by pharmacogenomics research and development innovator PharmaGenoma, Inc. and its subsidiary HairDX, LLC. (www.hairdx.com)

23 Sep 2009

Women have higher incidence of stroke and mortality than men

Even though the incidence of atrial fibrillation is higher in men than women, a review of past studies and medical literature completed by cardiac experts at Rush University Medical Center shows that women are more likely than men to experience symptomatic attacks, a higher frequency of recurrences, and significantly higher heart rates during atrial fibrillation, which increases the risk of stroke.

23 Sep 2009

Astellas partners with NSTA to sponsor a year-long program for science educators

Astellas Pharma US, Inc. ("Astellas"), in partnership with the National Science Teachers Association (NSTA), is pleased to welcome its second-year class of Chicago-area science teachers to participate in the 2009 NSTA New Science Teacher Academy.

22 Sep 2009

Dermatology News and Research

Latest Dermatology News and Research

KYTHERA Biopharmaceuticals presents its two Phase 2 clinical study results

First prescription foam formulation of benzoyl peroxide available

Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption

TriPollar technology effective in reducing stretch marks

Two-thirds of women say psoriasis negatively affects their overall emotional well-being

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Intoxicated trauma patients have higher survial rates than sober patients: Study

Lumenis announces launch of the AcuPulse Fractional CO2 Laser System for Aesthetics

Valeant Pharmaceuticals to acquire Private Formula International Holdings

Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis

NHGRI announces grant to establish Wisconsin Center of Excellence in Genomics Science

Halozyme Therapeutics announces Phase 1 clinical study to assess three insulin analogs

Child health experts to gather in Italy for Excellence in Paediatrics conference

Rio Grande Dermatology offers eyelash drugs for $99

Symposium on genetics of psoriasis and psoriatic arthritis to be held

NIHR to fund patient panel for skin disease research

LEO Pharma re-acquires product licensing rights from Warner Chilcott

Advanced Hair Studio to introduce genetic baldness tests in Australia

Women have higher incidence of stroke and mortality than men

Astellas partners with NSTA to sponsor a year-long program for science educators

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Dermatology News and Research

Latest Dermatology News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in